# US 2025/0325599 A1 · A clinical isolated avirulent strain protects against wildtype virulent clostridioides difficile infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325599 A1
- Document ID: US20250325599A1
- Status: Published application
- Kind: A1
- Application number: 18/870,325
- Filed: 2023-05-31
- Published: 2025-10-23
- Earliest claimed: 2022-05-31
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Eric PAMER; Qiwen DONG
- Web page: https://patentgrep.com/patent/US20250325599A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- C12N 15/75: for Bacillus
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C07K 14/33: from Clostridium (G)
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12N 1/36: Adaptation or attenuation of cells
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/689: for bacteria
- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- A61K 2039/522: {avirulent or attenuated}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2795/14021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/14041: Use of virus, viral particle or viral elements as a vector
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12R 2001/145: Clostridium
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Aspects herein concern cdtR mutations that can lead to reduced or absent virulence in C. difficile bacteria. Disclosed are compositions and methods using the cdtR mutants to treat or prevent C. difficile infections or diseases caused by C. difficile. Also disclosed are methods for detecting or determining C. difficile virulence based on mutation status of the cdtR gene in C. difficile.

## Claims

### Claim 1

A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient a C. difficile cell having a reduced cdtR protein expression relative to a wild type C. difficile.

### Claim 2

A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient a C. difficile cell that expresses a mutant cdtR protein.

### Claim 3

A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient a C. difficile cell that does not express a functional cdtR protein.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the C. difficile cell has a mutant cdtR gene relative to wild type C. difficile.

### Claim 5 (depends on 4)

The method of claim 4, wherein the mutant comprises a nonsense mutation.

### Claim 6 (depends on 4, 5)

The method of claim 4 or 5, where the mutant comprises a single nucleotide variation.

### Claim 7 (depends on 4, 5, 6)

The method of any one of claims 4-6, wherein the mutant comprises a deletion.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein the C. difficile cell is an engineered C. difficile cell.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein the C. difficile cell is C. difficile ST1-75 (ATCC Deposit Number PTA-127589).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein the C. difficile cell is C. difficile ST1-35 (ATCC Deposit Number PTA-127588).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the C. difficile cell is C. difficile cdtRmut6.1

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the C. difficile cell is C. difficile cdtRmut8.1

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, further comprising administering to the subject at least one additional C. difficile cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein the additional C. difficile cell is C. difficile ST1-75 (ATCC Deposit Number PTA-127589), C. difficile ST1-35 (ATCC Deposit Number PTA-127588), C. difficile cdtRmut6.1, or C. difficile cdtRmut8.1.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any of claims 1-14, further comprising administering to the subject one or more antibiotics after administering the C. difficile cell.

### Claim 16

A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile ST1-75 (ATCC Deposit Number PTA-127589).

### Claim 17

A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile ST1-35 (ATCC Deposit Number PTA-127588).

### Claim 18

A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile ST1-75 (ATCC Deposit Number PTA-127589).

### Claim 19

A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile ST1-35 (ATCC Deposit Number PTA-127588).

### Claim 20

A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile cdtRmut6.1.

### Claim 21

A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile cdtRmut8.1.

### Claim 22

A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile cdtRmut6.1.

### Claim 23

A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile cdtRmut8.1.

### Claim 24

A Clostridioides difficile (C. difficile) cell that expresses a mutant cdtR protein.

### Claim 25

A C. difficile cell having a reduced cdtR protein expression relative to a wild type C. difficile.

### Claim 26

A C. difficile cell that does not express a functional cdtR protein.

### Claim 27 (depends on 24, 25, 26)

The C. difficile cell of any of claims 24-26, wherein the C. difficile cell has a mutant cdtR gene relative to wild type C. difficile.

### Claim 28 (depends on 27)

The C. difficile cell of claim 27, wherein the mutant comprises a nonsense mutation.

### Claim 29 (depends on 27, 28)

The C. difficile cell of claim 27 or 28, where the mutant comprises a single nucleotide variation.

### Claim 30 (depends on 27, 28, 29)

The C. difficile cell of any one of claims 27-29, wherein the mutant comprises a deletion.

### Claim 31 (depends on 24, 25, 26, 27, 28, 29, 30)

The C. difficile cell of any of claims 24-30, wherein the C. difficile cell is an engineered C. difficile cell.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30, 31)

A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient the C. difficile cell of any of claims 24-31.

### Claim 33 (depends on 32)

The method of claim 32, further comprising administering to the subject one or more antibiotics after administering the C. difficile cell.

### Claim 34

A composition comprising two or more of C. difficile ST1-75 (ATCC Deposit Number PTA-127589), C. difficile ST1-35 (ATCC Deposit Number PTA-127588), C. difficile cdtRmut6.1, and C. difficile cdtRmut8.1.

### Claim 35

A method for analyzing virulence of a bacteria strain present in an infection in a patient, the method comprising identifying a cdtR gene in the bacteria strain.

### Claim 36 (depends on 35)

The method of claim 35, wherein the bacteria strain is a C. difficile bacteria strain.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein the cdtR gene is a cdtR gene present in a virulent bacteria strain.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the cdtR gene is a wild-type cdtR gene.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35-38, wherein the C. difficile bacteria strain is R20291.

### Claim 40 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the cdtR gene is a mutant cdtR gene relative to a wild type cdtR gene in C. difficile.

### Claim 41 (depends on 40)

The method of claim 40, wherein the mutant comprises a nonsense mutation.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, where the mutant comprises a single nucleotide variation.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40-42, wherein the mutant comprises a deletion.

### Claim 44 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 35-43, wherein the infection is present in the colon of the patient.

### Claim 45 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 35-44, wherein the identifying step comprises sequencing.

### Claim 46 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 35-45, wherein the identifying step comprises PCR.

### Claim 47 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 35-46, wherein the identifying step comprises comparing the cdtR gene identified to a standard.

### Claim 48 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 35-47, wherein the method further comprises administering a therapeutic intervention to the patient.

### Claim 49 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 34, 48)

The method of claim 48, wherein the therapeutic intervention comprises the C. diff cell of any one of claims 24-31 or the composition of claim 34.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein the therapeutic intervention comprises an antibiotic.

### Claim 51

A method of treating a bacterial infection in a patient, the method comprising administering a therapeutic intervention to the patient, wherein a cdtR gene has been identified in the bacterial infection.

### Claim 52 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 34, 51)

The method of claim 51, wherein the therapeutic intervention comprises the C. diff cell of any one of claims 24-31 or the composition of claim 34.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the therapeutic intervention comprises an antibiotic.

### Claim 54 (depends on 51, 52, 53)

The method of any one of claims 51-53, wherein the cdtR gene identified in the bacterial infection is a wild-type cdtR gene.

### Claim 55 (depends on 51, 52, 53, 54)

The method of any one of claims 51-54, wherein the cdtR gene identified in the bacterial infection is a cdtR gene found in a virulent C. difficile strain.

### Claim 56 (depends on 51, 52, 53, 54, 55)

The method of any one of claims 51-55, wherein the bacterial infection comprises R20291.

### Claim 57

A method of reducing virulence of a bacterium, the method introducing a cdtR mutant gene to the bacterium.

### Claim 58 (depends on 57)

The method of claim 57, wherein the mutant gene comprises a nonsense mutation.

### Claim 59 (depends on 57, 58)

The method of claim 57 or 58, where the mutant gene comprises a single nucleotide variation.

### Claim 60 (depends on 57, 58, 59)

The method of any one of claims 57-59, wherein the mutant gene comprises a deletion.

### Claim 61 (depends on 57, 58, 59, 60)

The method of any one of claims 57-60, wherein the bacterium is a C. difficile bacterium.

### Claim 62 (depends on 57, 58, 59, 60, 61)

The method of any one of claims 57-61, wherein the bacterium is R20291.

### Claim 63 (depends on 57, 58, 59, 60, 61, 62)

The method of any one of claims 57-62, wherein the cdtR mutant gene is introduced by infecting the bacterium with a bacteriophage that encodes the cdtR mutant gene.

### Claim 64 (depends on 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 57-63, wherein the cdtR mutant gene is introduced by engineering the bacterium.

### Claim 65 (depends on 64)

The method of claim 64, wherein the engineering comprises knocking out the wild-type cdtR gene.

### Claim 66 (depends on 64)

The method of claim 64, wherein the engineering comprises mutating the cdtR gene.

### Claim 67 (depends on 64, 65, 66)

The method of any one of claims 64-66, wherein the engineering comprises editing the wild-type cdtR gene by CRISPR-mediated genome editing.

### Claim 68

A bacteriophage comprising an engineered genome encoding a cdtR mutant gene.

### Claim 69 (depends on 68)

The bacteriophage of claim 68, wherein the mutant gene comprises a nonsense mutation.

### Claim 70 (depends on 68, 69)

The bacteriophage of claim 68 or 69, where the mutant gene comprises a single nucleotide variation.

### Claim 71 (depends on 68, 69, 70)

The bacteriophage of any one of claims 68-70, wherein the mutant gene comprises a deletion.

### Claim 72 (depends on 68, 69, 70, 71)

The bacteriophage of any one of claims 68-71, wherein the bacteriophage is derived from phiCD75-2 and/or phiCD75-3.
